Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule therapies for serious neuromuscular and cardiac diseases. The company operates within the biotechnology and pharmaceutical research industry and concentrates on precision medicines that target the underlying mechanisms of muscle dysfunction rather than symptom management.
The company’s primary value is driven by its pipeline of muscle-directed therapeutics, led by EDG-5506, a selective myosin modulator in clinical development for Duchenne muscular dystrophy (DMD) and related dystrophinopathies, and EDG-7500, a cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy (HCM). Edgewise targets patients with high unmet medical needs and positions itself through deep expertise in muscle biology and small-molecule drug design. Founded in 2017, the company emerged from scientific and operational experience developed in prior muscle-focused biotechnology efforts and became publicly traded in 2021.
Business Operations
Edgewise Therapeutics operates as a single-reportable research and development segment, generating no commercial revenue as of the most recent public filings. The company’s operations are centered on advancing its clinical pipeline through preclinical research, clinical trials, regulatory engagement, and manufacturing scale-up via third-party partners. Its core assets are internally developed small-molecule compounds designed to modulate myosin activity with high tissue selectivity.
The company conducts most research activities internally while relying on contract research organizations for clinical trial execution and external manufacturers for drug substance and product supply. As of available public disclosures, Edgewise does not report material revenue-generating partnerships, commercial subsidiaries, or joint ventures. Data regarding any minor subsidiaries or inactive legal entities is inconclusive based on available public sources.
Strategic Position & Investments
Edgewise’s strategic direction centers on advancing late-stage clinical development of its lead neuromuscular and cardiac programs while expanding its pipeline through continued investment in muscle biology and translational science. The company prioritizes diseases where existing treatments are limited or invasive and where small-molecule oral therapies may offer differentiated clinical and quality-of-life benefits.
Since its initial public offering, Edgewise has invested primarily in internal R&D rather than acquisitions, and no material acquisitions have been publicly disclosed. Its portfolio is focused on emerging muscle-targeted therapeutics, particularly selective myosin modulation, an area where the company seeks to establish long-term leadership through first- or best-in-class candidates.
Geographic Footprint
Edgewise Therapeutics is headquartered in Boulder, Colorado, which serves as the center for its executive leadership, research, and development activities. The company’s operations are primarily based in the United States, with clinical trials conducted at multiple investigational sites.
While the company does not maintain large international offices, its clinical development programs have involved investigational sites and regulatory interactions in North America and potentially Europe, depending on trial design. International operational influence is primarily indirect and conducted through global service providers rather than owned facilities.
Leadership & Governance
Edgewise was co-founded by industry executives with prior experience in muscle-focused drug development. The leadership team emphasizes scientific rigor, disciplined capital allocation, and long-term value creation through clinically differentiated assets.
Key executives include:
- Kevin Koch – President and Chief Executive Officer
- Joanne Donovan – Chief Medical Officer (data inconclusive based on available public sources)
- Randal Mills – Chief Financial Officer (data inconclusive based on available public sources)
The company is governed by a board composed of biotechnology, clinical, and capital markets professionals, with a strategic vision centered on translating muscle biology into scalable, disease-modifying therapies.